From: A stratified adaptive two-stage design with co-primary endpoints for phase II clinical oncology trials
Response
Non-toxicity
Negative
XR1-~B(N1-,pR-)
XT1-~B(N1-,pT-)
XR2-~B(N2-,pR-)
XT2-~B(N2-,pT-)
Positive
XR1+~B(N1+,pR+)
XT1+~B(N1+,pT+)
XR+~B(N+,pR+)
XT+~B(N+,pT+)
XR2e+~B(N2e+,pR+)
XT2e+~B(N2e+,pT+)